CMS Open Payments · Program Year 2024
Zak Ortho
Zak Ortho reported $11,421.32 across General Payments, Research, and Ownership to 116 physicians and teaching hospitals across 116 transactions.
- $11.4K Below-median payer
- All-tracks total
- 116 Below-median volume
- Transactions
- 116 Below-median reach
- Recipients
- #1627
- of 1,925 companies
Zak Ortho reported $11,421.32 across all CMS Open Payments tracks (General + Research + Ownership) to 116 physicians and teaching hospitals in Program Year 2024 - ranking #1627 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $11,421.32, averaging $98.46 per recipient.
How Zak Ortho's $11.4K all-tracks total breaks down
Zak Ortho's payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
14/100
Total payments
F
10/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
F
23/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer zak-ortho Zak Ortho
$11.4K · #1627/1,925 · 0.0% industry · PY2024
- TOT $11.4K
- RANK #1627
- SHARE 0.0%
- TXN 116
- RCP 116
- CAT 2
- GEN $11.4K
- TOP1 9.9%
- PY 2024
Volume peers
Nearest volume peer: Maxx Health Inc ($11.5K)
Zak Ortho sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Zak Ortho
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Zak Ortho, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
42 transactions worth $7.6K make "Travel and Lodging" the top general-payment category in the 2-category breakdown below, 66.7% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Travel and Lodging" leads Zak Ortho's 2-category general-payment breakdown at $7.6K, 66.7% of the reported total.
How Zak Ortho divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $7.6K | 42 | 66.7% |
| Food and Beverage | $3.8K | 74 | 33.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $4,895.55 (42.9%) of $11,421.32 in this company's General Payments records across 37 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Zak Ortho
The five named recipients with the highest reported General Payments from this company
- 1
Patrick O'callaghan
$1,129.68 across 7 reported transactions
- 2
Matthew Karek
$1,096.70 across 6 reported transactions
- 3
Alex Flach
$913.08 across 15 reported transactions
- 4
Joshua Veenstra
$888.04 across 12 reported transactions
- 5
Amanda Wrozek
$868.05 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Zak Ortho ranks #1627 of 1,925 by total payments (bottom 16% by spend) but is notably more concentrated than that alone would suggest -- #1,217 of 1,838 by HHI (bottom 34% least concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- Arthrosurface Incorporated : $1.8K total payments, HHI 636
- B. Braun Interventional Systems Inc. : $271.8K total payments, HHI 635
- Aesculap, Inc. : $921.5K total payments, HHI 634
- Ultragenyx Pharmaceutical Inc. : $454.6K total payments, HHI 634
- Pulmonx Corporation : $847.7K total payments, HHI 633
- SurGenTec : $704.8K total payments, HHI 632
- Zak Ortho (this company) : $11.4K total payments, HHI 631
- Bio-Rad Laboratories, Inc. : $421.2K total payments, HHI 631
- MorphoSys, US Inc. : $36.1K total payments, HHI 630
- Hologic Inc : $1.0M total payments, HHI 626
- J2 Bio-Pharma LLC : $1.6K total payments, HHI 625
- Suvon Surgical Llc : $96.2K total payments, HHI 623
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Zak Ortho's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Zak Ortho.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Zak Ortho.
Showing 6 of 1,924 companies with CMS-reported payment data.
Xenco Medical LLC
Biolase MG LLC
Biobeat USA Inc.
Greiner Bio-One North America, Inc.
EnableCV Inc.
Put this to use
Zak Ortho ranks #1627 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just Zak Ortho. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.